Stock Track | Galapagos NV Plummets 13.49% Pre-market on Massive Q2 Earnings Miss and Swing to Loss

Stock Track07-24

Shares of Galapagos NV (GLPG) are set to open sharply lower in pre-market trading on Thursday, plunging 13.49% following the release of the company's disappointing second-quarter and first-half 2025 financial results. The biotechnology firm reported significant losses that fell well short of analyst expectations, raising concerns about its financial health and future prospects.

Galapagos posted a quarterly adjusted loss of €1.60 per share for the quarter ended June 30, a dramatic reversal from the €0.14 earnings per share reported in the same quarter last year. This result significantly missed the mean expectation of six analysts, who had forecast a loss of €0.20 per share. Adding to the disappointment, revenue declined by 16.2% to €65.29 million, falling short of the €70.60 million analysts had anticipated.

The company's financial struggles were further highlighted in its half-year results, with Galapagos reporting a loss of €3.93 per diluted share for the first six months of 2025, compared to a profit of €1.51 per share in the same period last year. Despite these challenges, half-year revenue remained unchanged at €140.3 million. The stark reversal in profitability and the revenue decline in Q2 have raised serious concerns about the company's near-term prospects, leading to the sharp sell-off in pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment